- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03466749
Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment in China (RESPECT)
April 11, 2019 updated by: Ling Tao, Xijing Hospital
A Real-world Study in China: the Safety and Efficacy of Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment
The aim of this Real-world study in China is evaluating the Safety and Efficacy of Paclitaxel Eluting Balloon Catheter in Coronary de-novo lesions(target vessel diameter:2.5mm-4.0mm)Treatment.
And the primary point of this study is the target lesion failure of 12 months after surgery.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
600
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shannxi
-
Xi'an, Shannxi, China, 710032
- Recruiting
- Ling Tao
-
Contact:
- Ling Tao
- Phone Number: +862984775183
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-78 years of age, male or non-pregnant female;
- patients with asymptomatic or symptomatic myocardial ischemia, stable or unstable angina pectoris, myocardial infarction with a course of more than two weeks, and patients with indications for percutaneous coronary intervention;
- the target lesions were primary, in situ coronary artery stenosis, located on one or two different coronary artery vessels, the number of target lesions on each coronary artery was not more than one;
- the length of the target lesion ≤ 26mm (visual), which can be covered by a single drug balloon (it is suggested that the balloon should cover at least 4mm healthy partition, 2 mm at each end; The reference diameter of target vessel was 2.5mm-4.0mm (visual);
- the stenosis degree of the target lesion was ≥ 70%;
- left ventricular ejection fraction ≥ 45%.
- patients who can understand the purpose of the trial, voluntarily participate and sign informed consent, and are willing to follow up the study.
Exclusion Criteria:
Related to patients:
- patients with myocardial infarction within two weeks;
- pregnant or lactating women;
- cardiogenic shock, acute infection, known bleeding or coagulation disorder, or active digestive tract; Patients with history of hemorrhage or ulcer, cerebral hemorrhage or subarachnoid hemorrhage, stroke within half a year;
- patients with a life expectancy less than one year or with difficulties in clinical follow-up;
- patients who had a history of PTCA or had other operations scheduled during the follow-up period of one year;
- patients who are participating in any other clinical study and who have not reached the main end point of the study;
- present or previous history of severe liver disease, and / or renal impairment: serum creatinine > 2.0 mg / dl( 176.8 umol / L) or undergoing hemodialysis therapy. Therefore, it does not meet the requirements of angiography;
- patients with left ventricular ejection fraction below 45%;
- for other reasons, the researchers did not think it was appropriate for a patient to be selected.
Related to lesions:
- left main lesion and the bifurcation with side branch >2.5 mm;
- the location of the lesion was less than 10 mm at the proximal end of the anterior descending branch, 5 mm in the circumflex branch and 5 mm in the proximal end of the right coronary artery.
- severe calcification and twisted lesions which can not be successfully predilated, are not suitable for drug balloon delivery and expansion.
- lesion length ≥ 26 mm;
- evidence of severe thrombosis in target vessels before intervention;
- lesions that cannot be treated with PTCA or other interventional techniques;
- after predilation of the target lesion, residual stenosis ≥ 30% or TIMI blood flow < 3, and / or obvious flow limiting dissection.
Exclusion criteria related to drugs:
- patients with bleeding constitution, anticoagulant or antiplatelet drugs;
- patients who cannot tolerate aspirin and / or clopidogrel or who have a history of neutropenia or thrombocytopenia or who have too severe liver failure to receive clopidogrel;
- patients known to be intolerant or allergic to heparin, contrast agents, paclitaxel, iopramide, rapamycin, polylactic acid-glycolic acid polymer, stainless steel, etc.
- leukopenia (leukocyte count < 3 × 109 / L and the course > 3 days) or neutropenia ANC < 1000 neutrophil / mm3 and the course> 3 days). Or patients had a history of thrombocytopenia (< 100,000 platelets / mm3;
- patients with a history of peptic ulcer or gastrointestinal bleeding in the past 6 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention group
Paclitaxel Eluting Balloon Catheter treatment
|
Paclitaxel Eluting Balloon Catheter
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TVF of 12 months after surgery
Time Frame: 12 months after surgery
|
target vessel failure of 12 months after surgery
|
12 months after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ling Tao, Ph.D.,M.D., Xijing Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 22, 2018
Primary Completion (Anticipated)
February 22, 2020
Study Completion (Anticipated)
December 31, 2020
Study Registration Dates
First Submitted
February 5, 2018
First Submitted That Met QC Criteria
March 14, 2018
First Posted (Actual)
March 15, 2018
Study Record Updates
Last Update Posted (Actual)
April 12, 2019
Last Update Submitted That Met QC Criteria
April 11, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Artery Disease
- Coronary Disease
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- KY20172081
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Disease
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
National Heart Centre SingaporeUnknownCoronary Heart DiseaseSingapore
Clinical Trials on Paclitaxel Eluting Balloon Catheter
-
University of UlmB. Braun Melsungen AGCompletedCoronary Artery Disease | Chronic Total Occlusion | Native Coronary ArteryGermany
-
Zhejiang Zylox Medical Device Co., Ltd.CompletedPeripheral Arterial Disease | Popliteal Artery Stenosis | Popliteal Artery Occlusion | Iliac Artery Occlusion | Femoral Artery Occlusion | Iliac Artery Stenosis | Femoral Artery Stenosis
-
CCRF Inc., Beijing, ChinaUnknownPercutaneous Coronary InterventionChina
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingPopliteal Artery Occlusion | Femoral Artery Occlusion | Femoral Artery Stenosis | Popliteal Arterial StenosisChina
-
Acotec Scientific Co., LtdRecruitingPeripheral Artery DiseaseChina
-
Acotec Scientific Co., LtdCompletedPeripheral Artery DiseaseChina
-
Shaare Zedek Medical CenterTerminatedDialysis Access DysfunctionIsrael
-
Fondazione Evidence per Attività e Ricerche Cardiovascolari...Unknown
-
Boston Scientific CorporationActive, not recruitingCoronary Artery DiseaseJapan